Clinical Trials Directory

Trials / Completed

CompletedNCT05430477

Characterizing In Vivo Oral Lesion Impedances

Status
Completed
Phase
Study type
Observational
Enrollment
114 (actual)
Sponsor
Ryan J. Halter · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to demonstrate a significant difference in electrical impedance between normal, benign, premalignant, and malignant oral lesions using a custom device. The secondary study objective is to create a database of in vivo electrical impedance spectra and images of oral lesions. This will be achieved by collecting Electrical Impedance sensing data and images from two cohorts of patients: Cohort I will consist of 200 patients undergoing oral lesion biopsies and Cohort II will be comprised of 50 patients scheduled for oral cancer resection. A maximum of 5 additional subjects will be initially enrolled in each Cohort to optimize data acquisition.

Detailed description

For this study, a novel small field-of-view EII probe will be used for recording impedances from oral lesions. The device is comprised of gold-plated electrodes with analog electronics located in the probe's tip, to minimize cable lengths and maximize the signal-to-noise ratio. A pressure sensor is embedded within the probe to reduce variability in the amount of pressure used when the probe is applied to soft tissue. The bioimpedance-sensing probe is designed to the following specifications in order to accurately assess oral lesions: 1. measurement precision \~85 dB, 2. accuracy \>99%, 3. bandwidth extending to 1 MHz, and 4. multi-frequency sample rate of \>10 impedance spectra per second. Similar to other EII systems the team has developed and deployed in vivo, the system complies with International Electrotechnical Commission (IEC) requirements for safety and essential performance of medical electrical equipment (IEC 60601-1). There are no known probes cleared by the FDA for this application. The study is not being conducted in order to evaluate the EII probe's safety or effectiveness in human subjects, nor to test the device for marketing or promotion.

Conditions

Interventions

TypeNameDescription
DEVICEElectrical impedance imaging using Non-Significant Risk device (EII probe)novel small field-of-view Non-Significant Risk device (EII probe)

Timeline

Start date
2022-08-29
Primary completion
2025-06-30
Completion
2025-08-20
First posted
2022-06-24
Last updated
2025-09-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05430477. Inclusion in this directory is not an endorsement.